Manuela Campiglio
Milan, 20133, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment.
Journal: Cells
Published: January 15, 2020
Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors.
Journal: Cells
Published: December 14, 2018
An innovative approach to evaluate preeclampsia risk in the first trimester of pregnancy.
Journal: Minerva ginecologica
Published: October 09, 2018
The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
Journal: BMC cancer
Published: October 04, 2017
CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.
Journal: Oncotarget
Published: September 10, 2015
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
Journal: Oncotarget
Published: April 22, 2015
"Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas.
Journal: Frontiers in oncology
Published: October 15, 2014
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
Journal: Cancer research
Published: August 29, 2014
Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 22, 2014
Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells.
Journal: Journal of cellular physiology
Published: February 21, 2014
Last Updated: 09/26/2026